Federated Hermes
CHRS icon

Federated Hermes’s Coherus Oncology CHRS Stock Holding History

Federated Hermes’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.82K Buy
4,873
+957
+24% +$1.56K ﹤0.01% 1884
2026
Q1 		$6.62K Buy
3,916
+1,976
+102% +$3.51K ﹤0.01% 1870
2025
Q4 		$2.75K Buy
1,940
+1,461
+305% +$2.13K ﹤0.01% 1949
2025
Q3 		$786 Buy
+479
New +$533 ﹤0.01% 2081
2024
Q4 		– Sell
-582
Closed -$605 – 2091
2024
Q3 		$605 Buy
+582
New +$798 ﹤0.01% 1990
2022
Q4 		– Sell
-4,223
Closed -$41K – 2178
2022
Q3 		$41K Buy
4,223
+1,498
+55% +$15.2K ﹤0.01% 1696
2022
Q2 		$20K Sell
2,725
-2,214
-45% -$19.3K ﹤0.01% 1763
2022
Q1 		$64K Buy
4,939
+708
+17% +$9K ﹤0.01% 1709
2021
Q4 		$68K Sell
4,231
-6,900
-62% -$121K ﹤0.01% 1754
2021
Q3 		$179K Buy
+11,131
New +$163K ﹤0.01% 1680
2021
Q2 		– Sell
-161
Closed -$2K – 2220
2021
Q1 		$2K Sell
161
-49,905
-100% -$847K ﹤0.01% 2116
2020
Q4 		$870K Buy
50,066
+425
+0.9% +$7.57K ﹤0.01% 1372
2020
Q3 		$910K Buy
+49,641
New +$923K ﹤0.01% 1268
2019
Q4 		– Sell
-329,979
Closed -$6.68M – 2222
2019
Q3 		$6.68M Sell
329,979
-227,259
-41% -$4.54M 0.02% 689
2019
Q2 		$12.3M Buy
+557,238
New +$9.68M 0.03% 507
2019
Q1 		– Sell
-1,348
Closed -$12K – 2155
2018
Q4 		$12K Sell
1,348
-134,723
-99% -$1.56M ﹤0.01% 1846
2018
Q3 		$2.25M Buy
136,071
+82,334
+153% +$1.46M 0.01% 1049
2018
Q2 		$752K Buy
53,737
+52,226
+3,456% +$748K ﹤0.01% 1368
2018
Q1 		$17K Buy
1,511
+80
+6% +$875 ﹤0.01% 1785
2017
Q4 		$13K Sell
1,431
-38
-3% -$407 ﹤0.01% 1833
2017
Q3 		$20K Buy
+1,469
New +$19.4K ﹤0.01% 1753
2016
Q1 		– Sell
-284,000
Closed -$6.52M – 2110
2015
Q4 		$6.52M Sell
284,000
-126,200
-31% -$3.25M 0.02% 516
2015
Q3 		$8.22M Hold
410,200
– – 0.03% 468
2015
Q2 		$11.9M Buy
+410,200
New +$10.4M 0.04% 433

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Federated Hermes's CHRS Position: Q2 2026 in Review

Federated Hermes increased its Coherus Oncology (CHRS) stake by 24% in Q2 2026, buying an estimated $1.56K and bringing the position to 4,873 shares worth $6.82K. The position accounts for ﹤0.01% of the portfolio, ranked #1884.

Federated Hermes first reported a position in CHRS in Q2 2015 and has held it in 24 quarters since. The position peaked at $12.3M in Q2 2019. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Federated Hermes held 4,873 shares of Coherus Oncology worth $6.82K as of Q2 2026.
  • Federated Hermes bought 957 Coherus Oncology shares in Q2 2026, an estimated $1.56K.
  • Coherus Oncology made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1884 holding.
  • Federated Hermes first reported a position in Coherus Oncology in Q2 2015 and has held it in 24 quarters since.
  • Federated Hermes's Coherus Oncology position peaked at $12.3M in Q2 2019.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.